Isomorphic Labs has raised US$2.1bn to scale its AI drug discovery engine, expand globally and progress its drug candidate pipeline towards the clinic.
Isomorphic Labs said the new capital will be used to continue developing and deploying its AI drug design engine, known as IsoDDE.
The company says the platform is designed to help identify and design potential medicines across different therapeutic areas.
The funding will also support the company’s plans to accelerate and expand its drug candidate pipeline towards the clinic.
Isomorphic Labs also plans to use the funding to support its hiring targets by adding AI, engineering, drug design and clinical specialists across its sites.
The company was founded in 2021 and is led by Sir Demis Hassabis, founder and chief executive, and Max Jaderberg, president.
Sir Hassabis said: “This funding round is a massive vote of confidence from a diverse group of top-tier international investors in our AI-first approach to drug design and development.
“Now that we have shown our approach is fundamentally sound, our focus is on scaling our technology to its full potential.
“This capital injection allows us to build out our drug design engine at scale, driving us forward in our mission to solve all disease.”
The financing round was led by Thrive Capital.
Existing backers Alphabet and GV also took part, alongside new investors MGX, Temasek, CapitalG and the UK Sovereign AI Fund.
Joshua Kushner, founder and chief executive of Thrive Capital, said: “We are humbled to have the opportunity to continue to support Isomorphic’s mission to solve all disease.
“Over the past year, our conviction in the team has only deepened as they’ve made significant progress in building a unified AI drug design engine to define a new age of drug discovery and design.”
MPs sound alarm over NHS patient data deal with Palantir
